Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This trial is a proof-of-concept pilot study aim to investigate the biologic and clinical
effects of early azithromycin treatment in children hospitalized with Respiratory Syncytial
Virus (RSV) bronchiolitis.
HYPOTHESES
In infants hospitalized with RSV bronchiolitis, azithromycin therapy (compared to placebo)
will result in:
1. Decreased concentrations of inflammatory mediators (IL-8 as primary outcome) in serum
and nasal wash measured on day 8 after randomization.
2. A smaller proportion of participants with recurrent (≥2) wheezing episodes during weeks
3-52 following randomization.